Trial Profile
An Open-label, Multi-national, Multi-center, Single-arm, Uncontrolled, Long-term Extension Study of Orally Administered Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH) Who Received Riociguat in a Bayer Clinical Trial
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Jun 2023
Price :
$35
*
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms RIALTO
- Sponsors Bayer
- 25 May 2022 Planned End Date changed from 28 Dec 2023 to 28 Dec 2025.
- 25 May 2022 Planned primary completion date changed from 28 Dec 2023 to 28 Dec 2025.
- 06 Jul 2020 Planned End Date changed from 28 Dec 2021 to 28 Dec 2023.